<ARTICLE> 5 <LEGEND> THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE CONSOLIDATED FINANCIAL STATEMENTS OF ARONEX PHARMACEUTICALS, INC. AND SUBSIDIARIES SET FORTH IN THE COMPANY'S FORM 10-K FOR THE TWELVE MONTHS ENDED DECEMBER 31, 1999 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS. </LEGEND> <MULTIPLIER> 1 <PERIOD-TYPE> 12-MOS <FISCAL-YEAR-END> DEC-31-1999 <PERIOD-END> DEC-31-1999 <CASH> 11,528,000 <SECURITIES> 8,724,000 <RECEIVABLES> 0 <ALLOWANCES> 0 <INVENTORY> 0 <CURRENT-ASSETS> 19,785,000 <PP&E> 5,479,000 <DEPRECIATION> 3,450,000 <TOTAL-ASSETS> 22,734,000 <CURRENT-LIABILITIES> 4,486,000 <BONDS> 0 <PREFERRED-MANDATORY> 0 <PREFERRED> 0 <COMMON> 23,000 <OTHER-SE> 14,708,000 <TOTAL-LIABILITY-AND-EQUITY> 22,734,000 <SALES> 0 <TOTAL-REVENUES> 12,382,000 <CGS> 0 <TOTAL-COSTS> 0 <OTHER-EXPENSES> 0 <LOSS-PROVISION> 0 <INTEREST-EXPENSE> 327,000 <INCOME-PRETAX> (14,094,000) <INCOME-TAX> 0 <INCOME-CONTINUING> (14,094,000) <DISCONTINUED> 0 <EXTRAORDINARY> 0 <CHANGES> 0 <NET-INCOME> (14,094,000) <EPS-BASIC> (0.65) <EPS-DILUTED> (0.65)